EMR vs ROK: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
EMR is the larger of the two ($93.86B market cap): the incumbent the market prices for continued execution (20.86x forward earnings, beta 1.21). ROK is the smaller challenger ($43.69B), priced similarly on forward earnings (23.57x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
EMR vs ROK: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | EMR | ROK | What it tells you |
|---|---|---|---|
| Market cap | $93.86B | $43.69B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 20.86 | 23.57 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 34.99 | 31.37 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.21 | 1.51 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 91% of range | 31% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 4.52 | 12.30 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how EMR and ROK affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EMR and ROK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EMR and ROK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Emerson Electric (EMR) do?
Emerson Electric is a global industrial-technology company focused on automation, helping manufacturers and process industries run their plants more efficiently, safely, and reliably. Over the past several years Emerson has transformed itself from a diversified industrial conglomerate into a more focused automation pure-play, divesting legacy businesses like its commercial and residential climate-technologies unit and acquiring software and measurement assets. Its core products include process control systems, measurement and analytical instruments, valves and actuators, software for plant operations, and test and measurement equipment, much of it sold under brands like DeltaV, Rosemount, Fisher, AspenTech, and NI (National Instruments). Customers span energy, chemicals, life sciences, power, water, food and beverage, and discrete manufacturing. Emerson makes money by selling this hardware and software plus recurring service, software subscriptions, and aftermarket parts, with a meaningful share of revenue tied to keeping installed systems running. The shift toward higher-margin software and recurring revenue, anchored by AspenTech, is central to its strategy. Emerson is headquartered in St. Louis, Missouri.
What does Rockwell Automation (ROK) do?
Rockwell Automation (ROK) is one of the largest pure-play industrial automation and digital transformation companies in the world. It provides the hardware, software, and services that factories and industrial facilities use to run, monitor, and optimize their operations: programmable logic controllers, drives, motor control, sensors, industrial networking, and the Allen-Bradley and FactoryTalk product families that are standards in many North American plants. Rockwell organizes its business around Intelligent Devices, Software and Control, and Lifecycle Services, and increasingly pairs its installed base of automation hardware with software, analytics, and recurring services. A long partnership with software firms and its acquisitions in areas like manufacturing-execution software, cybersecurity, and information solutions position it to sell connected, data-driven factory systems, not just discrete controllers. Founded in 1903 and headquartered in Milwaukee, Wisconsin, Rockwell is an S&P 500 industrial that benefits from secular trends in reshoring, factory modernization, and the digitization of manufacturing, while remaining tied to the capital-spending cycles of its industrial customers.
EMR vs ROK: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- EMR drivers: Automation pure-play transformation; Software and recurring revenue.
- ROK drivers: Installed base and switching costs; Software, recurring revenue, and analytics.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. For ROK, rockwell's results are tied to industrial and manufacturing capital-spending cycles, so demand can soften in downturns or when customers delay projects, and orders can be lumpy.
EMR or ROK: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick EMR if you believe its drivers more; ROK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EMR and ROK guides.
EMR vs ROK: the full fundamentals
EMR. Emerson closed near $162 on October 16, 2026, close to its 52-week high of ~$166 after a ~19% YTD gain, and trades at about 22 times forward earnings and ~17 times EV/EBITDA, a premium to the average industrial. The market is paying for the software-heavy mix, ~27% operating margins and steady beats. Consensus for the November 4 fiscal Q4 report is ~$1.85 EPS on ~$5.1 billion of revenue.
ROK. Rockwell trades at a premium multiple relative to the broader industrials group, a gap explained by its pure-play automation focus, strong installed-base moat, and growing software mix: ~40 times trailing GAAP earnings, ~29 times forward estimates and ~24 times EV/EBITDA as of October 16, 2026. The trailing multiple overstates the premium because GAAP earnings are still recovering from fiscal 2025; on analysts' fiscal 2027 estimate of ~$14.92 the stock is near 29 times. The 25 analysts tracked carry a mean target near $476, and the fiscal fourth-quarter report expected around November 5, 2026 is the next catalyst for the multiple.
Headline figures (approximate, October 2026): EMR shows revenue (ttm) ~$18.6B, revenue growth (june 2026 qtr, yoy) ~+7%, operating margin ~27%, net income (ttm) ~$2.6B; ROK shows revenue (ttm) ~$8.97 billion (June 2026 quarter up ~8% year over year), margins (ttm) ~49% gross, ~21% operating, ~13% net, net income (ttm) ~$1.2 billion; trailing EPS ~$10.68, adjusted eps, june 2026 quarter $3.49 vs ~$3.38 consensus.
The bottom line: EMR vs ROK
EMR and ROK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined EMR and ROK exposure against your real portfolio. It is not an investment adviser.
Wondering how EMR or ROK fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Emerson Electric
Ask Walnut's AI anything about EMR and see how it fits what you own.
FAQ
What is the difference between EMR and ROK?
+
Emerson Electric is a global industrial-technology company focused on automation, helping manufacturers and process industries run their plants more efficiently, safely, and reliably. Rockwell Automation (ROK) is one of the largest pure-play industrial automation and digital transformation companies in the world. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is EMR or ROK the better stock?
+
Neither is universally better. EMR is the larger incumbent; ROK is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, EMR or ROK?
+
On forward P/E (as of November 2026), EMR trades at 20.86x and ROK at 23.57x, so EMR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both EMR and ROK?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of EMR vs ROK?
+
EMR: Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. The transformation through large acquisitions like AspenTech and NI carries integration, execution, and valuation risk, and the company took on debt and complexity to fund deals (about $13.8 billion of debt against ~$2.2 billion of cash). Competition in automation and industrial software is intense, including from larger and lower-cost rivals. Foreign-exchange effects, supply-chain disruptions, and project delays can pressure results. After a ~19% run in 2026, the stock trades at about 36 times trailing and 22 times forward earnings, so expectations into the November 4 report are elevated, and the payoff from the software pivot must still prove out fully. ROK: Rockwell's results are tied to industrial and manufacturing capital-spending cycles, so demand can soften in downturns or when customers delay projects, and orders can be lumpy. It competes with large global automation rivals like Siemens, Schneider Electric, ABB, and Emerson, several of which have broader geographic and product breadth. Exposure to specific end markets (autos, semiconductors, food and beverage, energy) introduces concentration and cyclicality. Supply-chain disruptions and component availability have affected lead times in the past. The stock often trades at a premium multiple for an industrial, so disappointing orders or margins can pressure the valuation. Valuation is the near-term pressure point: at ~40 times trailing and ~29 times forward earnings in mid-October 2026, the stock sits below several recently trimmed analyst targets (Morgan Stanley cut its target to $520 from $545 and Mizuho to $430 from $445), and it has fallen ~8% over three months. Debt of ~$3.6 billion against ~$479 million of cash is manageable but higher than the company carried before recent acquisitions.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell EMR or ROK; figures are approximate and dated (as of November 2026). Verify current data before investing.